Neurophysiology and Pharmacology of Cough Reflex Hypersensitivity
Brief Summary
A cough lasting more than 2 months is known as a chronic cough, affecting 12-23% of the adult non-smoking population. Chronic cough has many associated complications including incontinence, muscular chest pains, blackouts and depression. Current treatment is often ineffective in these patients. To develop new medications the investigators need to understand more about the mechanisms that can lead to excessive coughing.
This study plans to compare a group of 12 healthy volunteers and 12 patients with a chronic cough. The investigators hypothesise that that chronic cough patients have a more sensitive cough reflex as a result central nervous system hyper-excitability (central sensitisation). The investigators will measure cough reflex sensitivity before and after administration of ketamine, a medication that blocks an important receptor in the central nervous system.
Intervention / Treatment
-
Ketamine (DRUG)Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
Condition or Disease
- Chronic Cough
Phase
Study Design
Study type: | INTERVENTIONAL |
---|---|
Status: | Completed |
Study results: | No Results Available |
Age: | 18 Years to 80 Years |
Enrollment: | 24 (ACTUAL) |
Funded by: | Other |
Allocation: | Randomized |
Primary Purpose: | Health Services Research |
MaskingDOUBLE:
|
Clinical Trial Dates
Start date: | Feb 01, 2008 | |
---|---|---|
Primary Completion: | Jul 01, 2009 | ACTUAL |
Completion Date: | Jul 01, 2009 | ACTUAL |
Study First Posted: | Mar 10, 2009 | ESTIMATED |
Results First Posted: | Aug 31, 2020 | |
Last Updated: | Jun 17, 2013 |
Sponsors / Collaborators
Lead Sponsor:
Jacky Smith
Responsible Party:
Jacky Smith
Location
Participant Groups
-
No description provided
-
No description provided
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 18 |
Maximum Age: | 80 |
Age Groups: | Adult / Older Adult |
Healthy Volunteers: | Yes |
Inclusion Criteria:
Healthy Volunteers:
* Over 18 years old
* Measurable cough reflex sensitivity
* No current or past history of chronic cough or chronic respiratory disease.
* No symptoms of gastro-oesophageal reflux disease, asthma or post-nasal drip.
Chronic Cough Patients
* Over 18 years old
* Chronic persistent cough (\> 8 weeks) despite investigation and/or treatment trials for cough variant asthma/post nasal drip and gastro-oesophageal reflux disease.
* Normal CXR
* Normal lung function
* Measurable cough reflex sensitivity
Exclusion Criteria:
* Recent Upper Respiratory Tract Infection (4 weeks)
* Pregnancy/breast feeding
* Current smokers or ex-smokers with \< 6 months abstinence or cumulative history of \> 10 packyears
* Diabetes Mellitus
* Opiate or ACE Inhibitor use.
* Any centrally acting medication which has the potential to alter cough reflex sensitivity.
* Significant and ongoing chronic respiratory, cardiovascular (in particular hypertension), gastro-intestinal, haematological (porphyria), neurological or psychiatric illness.
* Drug or alcohol abuse
* History of allergy or reaction to ketamine of other NMDA receptor antagonists.
Healthy Volunteers:
* Over 18 years old
* Measurable cough reflex sensitivity
* No current or past history of chronic cough or chronic respiratory disease.
* No symptoms of gastro-oesophageal reflux disease, asthma or post-nasal drip.
Chronic Cough Patients
* Over 18 years old
* Chronic persistent cough (\> 8 weeks) despite investigation and/or treatment trials for cough variant asthma/post nasal drip and gastro-oesophageal reflux disease.
* Normal CXR
* Normal lung function
* Measurable cough reflex sensitivity
Exclusion Criteria:
* Recent Upper Respiratory Tract Infection (4 weeks)
* Pregnancy/breast feeding
* Current smokers or ex-smokers with \< 6 months abstinence or cumulative history of \> 10 packyears
* Diabetes Mellitus
* Opiate or ACE Inhibitor use.
* Any centrally acting medication which has the potential to alter cough reflex sensitivity.
* Significant and ongoing chronic respiratory, cardiovascular (in particular hypertension), gastro-intestinal, haematological (porphyria), neurological or psychiatric illness.
* Drug or alcohol abuse
* History of allergy or reaction to ketamine of other NMDA receptor antagonists.
Primary Outcomes
-
Cough Reflex Sensitivity 6 months
Secondary Outcomes
-
Upper Oesophageal Pain Thresholds 6 months
-
Pain Thresholds Pharynx 6 months
-
Pain Thresholds Chest Wall 6 months
More Details
NCT Number: | NCT00858624 |
---|---|
Other IDs: | 07/H1004/142 |
Study URL: | https://clinicaltrials.gov/study/NCT00858624 |
Last updated: Sep 29, 2023